Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
MediciNova Inc Market Cap
Based on ratings from 2 stock analysts, the MediciNova Inc stock price is expected to increase by 268.73% in 12 months. This is calculated by using the average 12-month stock price forecast for MediciNova Inc. The lowest target is $6 and the highest is $10. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assignedMNOV 2 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect MediciNova Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on MNOV. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of MNOV.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason Kolbert D. Boral Capital | Buy | $9 | Maintains | Dec 6, 2024 |
| Jason Kolbert D. Boral Capital | Buy | $9 | Initiates | Dec 2, 2024 |
| Jason McCarthy Maxim Group | Buy | $15 | Initiates | Mar 10, 2021 |
B. Riley FBR | Buy | Maintains | Mar 13, 2020 | |
| Mayank Mamtani B. Riley Securities | Buy | $11 | Maintains | Mar 13, 2020 |
B. Riley FBR | Buy | Initiates | May 5, 2018 | |
B. Riley FBR | Buy | Initiates | Mar 28, 2018 | |
B. Riley Securities | Buy | Initiates | Mar 28, 2018 | |
Ladenburg Thalmann | Buy | $10.5 | Maintains | May 24, 2012 |
When did it IPO
2006
Staff Count
13
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Yuichi Iwaki M.D., Ph.D.
Market Cap
$110.8M
In 2023, MNOV generated $1.0M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MNOV's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MediciNova, Inc. (NASDAQ: MNOV) will present interim results from its COMBAT-ALS clinical trial of MN-166 for ALS at an international symposium from December 6-8, 2024, in Montreal.
Why It Matters - The announcement of interim results from a critical clinical trial for ALS could impact MediciNova's stock price, influencing investor sentiment and potential future funding.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MediciNova, Inc. (NASDAQ:MNOV) has received a Notice of Allowance for a patent on MN-001 (Tipelukast) to reduce liver triglyceride synthesis, beneficial for insulin resistance and diabetes. Patent expires 2042.
Why It Matters - The patent allowance for MN-001 enhances MediciNova's competitive position, potentially increasing its market value and revenue prospects in treating metabolic disorders, appealing to investors.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MediciNova, Inc. announced a settlement in the Sanofi/Novartis litigation, resulting in the company receiving monetary damages. Further details will be disclosed later.
Why It Matters - MediciNova's entitlement to monetary damages from the Sanofi/Novartis settlement could boost its financial position and shareholder value, potentially influencing stock performance positively.
Wed, 23 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MediciNova, Inc. (NASDAQ:MNOV) updated its Phase 2/3 trial of MN-166 for ALS at the 2024 NEALS Meeting. The presentation was led by Dr. Björn Oskarsson.
Why It Matters - The update on the Phase 2/3 trial for MN-166 in ALS signals potential advancements in treatment, influencing investor sentiment and stock performance for MediciNova.
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MediciNova, Inc. (NASDAQ: MNOV) received a $22 million grant from the NIH for an Expanded Access Protocol to assess MN-166's efficacy in treating ALS.
Why It Matters - The $22 million NIH grant enhances MediciNova's credibility and financial stability, potentially boosting stock value and attracting more investors due to its focus on ALS treatment.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - MediciNova, Inc. (NASDAQ: MNOV) announced a poster presentation for its MN-166 clinical trial in ALS at the 35th International Symposium on ALS/MND, December 6-8, 2024, in Montreal.
Why It Matters - The presentation of clinical trial results for MN-166 in ALS may influence MediciNova's stock value, reflecting potential advancements in treatment and investor sentiment in the biotech sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
